Canada Moved Two Cancer Drugs Forward in One Week. Neither Went the Normal Route.
One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.
Perjeta
One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.